Bullish case
$65 to $80
More likely if same-facility revenue sustains 7%+ growth, JV hospitals ramp above plan, legal overhang resolves cleanly, leverage drops below 3.5x, and the market re-rates ACHC toward a mid-to-high-20s forward multiple.
Acadia Healthcare Company research snapshot
ACHC AI Stock Analysis
ACHC AI stock analysis currently reads Acadia Healthcare as the largest stand-alone behavioral healthcare company in the United States, with roughly 275 facilities and about 12,400 beds across 40 states and Puerto Rico. The stock has staged a dramatic recovery from a $11.43 low in late 2025 to a $31.28 close on July 10, 2026, driven by operational restructuring, raised 2026 guidance, eight consecutive quarters of improved staff retention, and new joint-venture hospital openings. At the July 13, 2026 data cutoff, the verified market capitalization is about $2.88 billion on roughly 90.53 million shares. The ACHC AI stock forecast uses scenario ranges rather than a single price target because the company is still in a turnaround, and Medicaid/Medicare policy, legal overhang, payor mix, same-facility growth, and leverage can change the trajectory quickly.
Current price
$31.28
Market cap
$2.88 billion verified market cap
AI score
54 / 100
Rating
Leading U.S. behavioral health provider in operational turnaround, still carrying legal, leverage, and goodwill impairment overhang
Trend status
Up more than 120% year to date from the $11.43 low, trading near the top of the 52-week range and above all key moving averages
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- B-level information richness. Acadia Healthcare has a decade-plus public record, quarterly earnings releases, SEC filings, analyst coverage from UBS, Deutsche Bank, and others, but the GAAP results are heavily distorted by impairment charges, requiring adjusted non-GAAP metrics for a clean view.
- bias Check
- The main AI research bias is treating the sharp YTD rally as confirmation that the turnaround is fully priced in. The counter-check is whether the 120% gain already reflects the best-case recovery and leaves no room for payor pressure, legal overhang, or leverage above 4x EBITDA.
- ai Confidence
- High for FY2025 revenue, Q1 2026 metrics, cash and debt, analyst estimates, and market-cap math. Medium for forward price ranges because the turnaround is still in progress, Q2 2026 earnings are due July 28, and GAAP distortions mean adjusted metrics drive the story more than reported net income.
- investment Certainty
- Low-medium at $31.28. The operational recovery story is compelling and management is executing, but the stock already reflects much of the improvement. Margin of safety is thin unless you assume continued same-facility growth, leverage reduction, and a clean legal outcome.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Acadia Healthcare operates the largest U.S. stand-alone behavioral health network. Revenue comes from inpatient acute psychiatric care, residential treatment, comprehensive treatment centers (methadone clinics), and specialty facilities, serving about 84,000 patients daily. | Medium-high |
| Moat | The moat comes from national scale in a fragmented market, certificate-of-need protections in some states, the largest U.S. methadone clinic chain, and entrenched referral relationships. But moat depth is limited because payors and regulators control rates, and competitors can build or acquire. | Medium |
| Management | Interim CEO Debra Osteen returned in January 2026 after former CEO Christopher Hunter departed. The team has restructured the acute division, improved staff retention, secured JV partnerships with Tufts Medicine, Orlando Health, and Methodist, and raised 2026 guidance. CFO departure planned adds a key-person risk. | Medium |
| Financial trend | FY2025 revenue was $3.31 billion, up about 5% YoY. Q1 2026 revenue grew 7.6% to $828.8 million, with same-facility revenue up 7.3%. Adjusted EBITDA rose 7.5% to $144.2 million, beating guidance. GAAP net income was only $4.1 million due to prior impairment charges, but adjusted EPS of $0.37 beat consensus. | Medium-high |
| Valuation | At $31.28, ACHC trades at about 0.84x TTM sales, 1.47x book value, 9.63x EV/EBITDA, and 20.83x forward adjusted EPS of about $1.50. Forward multiples reflect a recovery premium after the 120% YTD rally. | Medium |
| Technical trend | Price is well above the 50-day and 200-day moving averages after the massive rally from $11.43. The stock is near the top of its 52-week range of $11.43 to $32.82. | Medium |
| Risk level | Main risks include the 2023 abuse settlement and SEC billing settlement, ongoing government investigations, net leverage near 4x adjusted EBITDA, $400M+ annual capex for bed expansion, payor denial trends, specialty segment headwinds, and a CEO departure and CFO transition. | Medium-high |
| AI confidence | Descriptive confidence is medium-high for adjusted financials and market data. Return confidence is lower because the YTD rally has already absorbed much positive news and the legal and leverage overhang could re-emerge. | Medium data confidence |
| Investment certainty | ACHC has a clear operational recovery thesis backed by improved metrics and guidance, but investment certainty at $31.28 is low-medium. The recovery is priced in to a degree that leaves limited margin of safety for legal, payor, or macroeconomic surprises. | Low-medium |
ACHC AI stock forecast
ACHC AI Stock Forecast Scenarios
The ACHC AI stock forecast is scenario-based because Acadia is still in a turnaround and behavioral health earnings depend on same-facility growth, payor mix, legal outcomes, leverage, and valuation multiples. Using the $31.28 price reference, forward adjusted EPS guidance midpoint near $1.50, and an audited three-year model with growth and PE assumptions of 20%/28x, 10%/22x, and -5%/15x, the mechanical outcomes are about $73 in a bullish case, $44 in a base case, and $19 in a bearish case.
Base case
$38 to $48
More likely if revenue grows near high single digits, adjusted EPS compounds toward company guidance, leverage stays near 4x, legal costs remain contained, and the stock keeps a low-20s forward multiple.
Bearish case
$16 to $22
More likely if payor denials accelerate, legal settlements exceed reserves, same-facility growth slows below 3%, leverage rises above 4.5x, or management turnover disrupts the turnaround.
ACHC AI technical analysis
ACHC AI Technical Analysis
ACHC AI technical analysis is extended after the powerful recovery from $11.43 as of the July 13, 2026 data cutoff. The July 10, 2026 close was $31.28. Third-party snapshots place the stock well above its 50-day and 200-day moving averages, with a 52-week range of about $11.43 to $32.82 and average volume near 1.8 to 2.5 million shares.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $31.28 | July 10, 2026 closing price from market data cross-checks. |
| Immediate support | $28 to $29.5 | This band brackets the recent pullback lows and the 20-day moving average area. |
| Deeper support | $24 to $26 | This area covers prior consolidation and the 50-day moving average zone. |
| Near resistance | $32 to $33 | The 52-week high near $32.82 is the immediate overhead supply zone. |
| Next resistance | $36 to $39 | This area covers a post-GFC structural resistance zone and the UBS analyst target near $39. |
| Moving averages | 50-day near $26 to $27, 200-day near $21 to $22 | Price is far above both averages after the YTD rally. A pullback toward the 50-day would be significant. |
| Momentum | Strong positive momentum from the $11.43 low but decelerating near the 52-week high | Momentum can stall or reverse at prior highs, especially if Q2 earnings do not deliver a clear beat. |
| Volume | Average volume near 1.8 to 2.5 million shares | Volume spikes on earnings, legal news, and guidance updates are the most actionable signals. |
| Volatility | Watch Q2 2026 earnings on July 28, legal developments, and bed-opening announcements | Behavioral health stocks can gap on legal outcomes, payor policy, and utilization trends. |
| Invalidation | Close below $28, then below $24 | A sustained break under $28 weakens the short-term uptrend. A break under $24 challenges the medium-term recovery. |
ACHC AI trading strategy
ACHC AI Trading Strategy Framework
The ACHC AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with same-facility growth, payor mix, legal developments, bed openings, leverage, and guidance.
Trend-following setup
Watch for ACHC to hold $28 to $29.5 and break through $32.82 (52-week high) with healthy volume, supported by raised guidance and no negative legal news.
A failed breakout followed by a close below $28 should reduce trend confidence, especially if Q2 2026 results miss or leverage expectations worsen.
Mean-reversion setup
If ACHC pulls back toward $26 to $28 without a fundamental reset, compare the lower price with forward adjusted EPS, free cash flow, net leverage trends, and peer comparisons to UHS and THC.
Do not treat every pullback as automatically attractive. Legal overhang and payor pressure can create false bottoms in behavioral health stocks.
Fundamental monitor
Track same-facility revenue growth, patient days, revenue per patient day, adjusted EBITDA margin, bed additions, JV hospital openings, net leverage, free cash flow, legal reserves, and guidance updates.
Position sizing should reflect that ACHC at $31.28 already prices significant recovery. Q2 2026 earnings on July 28 are the next catalyst that will confirm or challenge the turnaround pace.
Investment research summary
Four-master Research Compression
Business essence
Patients, families, and payers fund Acadia Healthcare because behavioral health treatment requires specialized facilities, clinical staff, and regulated care that most general hospitals do not provide at scale. The business converts that need into revenue through per-day or per-case payments across inpatient, residential, and outpatient settings.
Moat
The moat rests on national scale, the largest U.S. methadone clinic chain with roughly 165 CTCs, certificate-of-need protections in some states, and referral relationships. The moat is narrow because payors control rates, competitors can expand, and regulatory or legal shocks can damage reputation and demand.
Munger risk inversion
The thesis fails if legal overhang produces larger settlements or criminal charges, if payor denials and bad debts rise faster than expected, if staff turnover returns, if leverage stays above 4.5x with no clear delevering path, or if the CFO departure signals deeper management instability.
Management
Interim CEO Debra Osteen is a known quantity who previously led Acadia. The restructuring has produced measurable improvement: eight quarters of better staff retention, JV partnerships with three health systems, a refocused acute division, and raised 2026 guidance. CFO departure raises team continuity risk.
Industry trend
Behavioral health demand benefits from rising awareness, greater insurance coverage for mental health and substance-use treatment, and the opioid crisis. The offset is that payors push for lower-cost outpatient settings, government reimbursement rates lag inflation, and regulatory scrutiny of the sector remains high.
Valuation and margin of safety
At $31.28 and 20.83x forward adjusted EPS of about $1.50, ACHC already prices a successful turnaround. Margin of safety would improve if leverage drops below 3.5x, legal overhang clears, and the stock pulls back to a mid-teens forward multiple.
Source-backed data
ACHC Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $31.28 close on July 10, 2026 | Yahoo Finance and market data cross-checks | July 13, 2026 |
| Market capitalization | $2.88 billion, verified against 90.53 million shares | Financial rigor market-cap check plus CompaniesMarketCap | July 13, 2026 |
| FY2025 revenue | $3.31 billion | Acadia Healthcare FY2025 earnings release | July 13, 2026 |
| Q1 2026 revenue and adjusted EPS | $828.8 million revenue and $0.37 adjusted EPS | Acadia Healthcare Q1 2026 earnings release | July 13, 2026 |
| Q1 2026 same-facility growth and adjusted EBITDA | 7.3% same-facility revenue growth, $144.2 million adjusted EBITDA | Acadia Healthcare Q1 2026 earnings release | July 13, 2026 |
| Cash and total debt | $158.47 million cash and about $2.66 billion total debt at March 31, 2026 | Acadia Healthcare Q1 2026 balance sheet | July 13, 2026 |
| 2026 guidance (raised) | Revenue $3.37B to $3.45B, Adjusted EBITDA $580M to $615M, adjusted EPS $1.35 to $1.60 | Acadia Healthcare Q1 2026 guidance update | July 13, 2026 |
| Facility footprint | Roughly 275 behavioral health facilities with about 12,400 beds across 40 states and Puerto Rico | Acadia Healthcare company description | July 13, 2026 |
| 52-week price range | $11.43 to $32.82 | Yahoo Finance and market data cross-checks | July 13, 2026 |
| Forward valuation snapshot | 0.84x TTM sales, 1.47x book, 9.63x EV/EBITDA, 20.83x forward adjusted P/E | Audited valuation math on verified price and fundamentals | July 13, 2026 |
| UBS analyst target | $39 price target, Buy rating (July 9, 2026) | UBS analyst note | July 13, 2026 |
Frequently Asked Questions
Read the UHS AI stock analysisView the THC AI stock forecastExplore the EHC AI technical analysisExplore the AI Stock PickerBuild an AI trading strategy
This ACHC AI stock analysis is an informational research tool only. It is not investment advice, a rating, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong if earnings, legal outcomes, payor policy, management changes, leverage, or market sentiment change.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it